Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(3.60) by 31.5...
Guggenheim analyst Subbu Nambi upgrades GRAIL (NASDAQ:GRAL) from Neutral to Buy and announces $100 price target.
Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $75 to $85.
The private placement included the participation by new and existing institutional investors, including Deep Track Capital, Far...
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and the Universit...
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and the Universit...
